The co‐localization of S1PR1 with GFAP or IBA‐1 and the reduction of IL‐1β and TNF‐α suggested that EA may exert beneficial effects via an anti‐inflammatory effect as an alternative therapy for AD. Here, GFAP is linked to Alzheimer disease.